The research of the Hansen group focuses on the development of new tool compounds that are capable of reverting chemoresistance in cancer. Of particular interest are: (1) selective histone deacetylase (HDAC) inhibitors, (2) inhibitors of protein-protein interactions, (3) multi-target drugs, and (4) new chemical modalities in drug discovery (e.g. PROTACs, chimeric small molecules). Our approach includes the synthesis of small molecules and peptidomimetics using various modern synthetic methods such as solid-phase synthesis, microwave-assisted synthesis as well as multicomponent reactions, biological evaluation of test compounds in target-based & phenotypic assays, and analysis of structure-activity relationships.